Federico Gatto1,2, Gianluca Trifirò3, Francesco Lapi4, Francesco Cocchiara5, Claudia Campana5, Carlotta Dell'Aquila5, Carmen Ferrajolo6, Marica Arvigo5,7, Claudio Cricelli8, Massimo Giusti5, Diego Ferone5,7. 1. Endocrinology, Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Genoa, Italy. fedgatto@hotmail.it. 2. Center of Excellence for Biomedical Research (CEBR), Policlinico San Martino, University of Genoa, Genoa, Italy. fedgatto@hotmail.it. 3. Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy. 4. Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy. 5. Endocrinology, Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Genoa, Italy. 6. Department of Experimental Medicine, Pharmacology Section, Campania Regional Centre of Pharmacovigilance and Pharmacoepidemiology, University of Campania, Naples, Italy. 7. Center of Excellence for Biomedical Research (CEBR), Policlinico San Martino, University of Genoa, Genoa, Italy. 8. Italian College of General Practitioners and Primary Care, Florence, Italy.
Abstract
PURPOSE: Epidemiological data are pivotal for the estimation of disease burden in populations. AIM: Of the study was to estimate the incidence and prevalence of acromegaly in Italy along with the impact of comorbidities and hospitalization rates as compared to the general population. METHODS: Retrospective epidemiological study (from 2000 to 2014) and case control-study. Data were extracted from the Health Search Database (HSD). HSD contains patient records from about 1000 general practitioners (GPs) throughout Italy, covering a population of more than 1 million patients. It includes information about patient demographics and medical data including clinical diagnoses and diagnostic tests. RESULTS: At the end of the study period, 74 acromegaly patients (out of 1,066,871 people) were identified, resulting in a prevalence of 6.9 per 100,000 inhabitants [95% CI 5.4-8.5]. Prevalence was higher in females than men (p = 0.004), and showed a statistically significant trend of increase over time (p < 0.0001). Overall, incidence during the study period was 0.31 per 100,000 person-years. Hypertension and type II diabetes mellitus were the comorbidities more frequently associated with acromegaly (31.3 and 14.6%, respectively) and patients were more likely to undergo a high frequency of yearly hospitalization (≥3 accesses/year, p < 0.001) compared to sex-age matched controls. CONCLUSIONS: This epidemiological study on acromegaly carried out using a large GP-based database, documented a disease prevalence of about 7 cases per 100,000 inhabitants. As expected, acromegaly was associated with a number of comorbidities (mainly hypertension and type II diabetes mellitus) and a high rate of patients' hospitalization.
PURPOSE: Epidemiological data are pivotal for the estimation of disease burden in populations. AIM: Of the study was to estimate the incidence and prevalence of acromegaly in Italy along with the impact of comorbidities and hospitalization rates as compared to the general population. METHODS: Retrospective epidemiological study (from 2000 to 2014) and case control-study. Data were extracted from the Health Search Database (HSD). HSD contains patient records from about 1000 general practitioners (GPs) throughout Italy, covering a population of more than 1 million patients. It includes information about patient demographics and medical data including clinical diagnoses and diagnostic tests. RESULTS: At the end of the study period, 74 acromegalypatients (out of 1,066,871 people) were identified, resulting in a prevalence of 6.9 per 100,000 inhabitants [95% CI 5.4-8.5]. Prevalence was higher in females than men (p = 0.004), and showed a statistically significant trend of increase over time (p < 0.0001). Overall, incidence during the study period was 0.31 per 100,000 person-years. Hypertension and type II diabetes mellitus were the comorbidities more frequently associated with acromegaly (31.3 and 14.6%, respectively) and patients were more likely to undergo a high frequency of yearly hospitalization (≥3 accesses/year, p < 0.001) compared to sex-age matched controls. CONCLUSIONS: This epidemiological study on acromegaly carried out using a large GP-based database, documented a disease prevalence of about 7 cases per 100,000 inhabitants. As expected, acromegaly was associated with a number of comorbidities (mainly hypertension and type II diabetes mellitus) and a high rate of patients' hospitalization.
Authors: Tirissa J Reid; Kalmon D Post; Jeffrey N Bruce; M Nabi Kanibir; Carlos M Reyes-Vidal; Pamela U Freda Journal: Clin Endocrinol (Oxf) Date: 2009-05-16 Impact factor: 3.478
Authors: Jakob Dal; Ulla Feldt-Rasmussen; Marianne Andersen; Lars Ø Kristensen; Peter Laurberg; Lars Pedersen; Olaf M Dekkers; Henrik Toft Sørensen; Jens Otto L Jørgensen Journal: Eur J Endocrinol Date: 2016-06-08 Impact factor: 6.664
Authors: Patrick Petrossians; Adrian F Daly; Emil Natchev; Luigi Maione; Karin Blijdorp; Mona Sahnoun-Fathallah; Renata Auriemma; Alpha M Diallo; Anna-Lena Hulting; Diego Ferone; Vaclav Hana; Silvia Filipponi; Caroline Sievers; Claudia Nogueira; Carmen Fajardo-Montañana; Davide Carvalho; Vaclav Hana; Günter K Stalla; Marie-Lise Jaffrain-Réa; Brigitte Delemer; Annamaria Colao; Thierry Brue; Sebastian J C M M Neggers; Sabina Zacharieva; Philippe Chanson; Albert Beckers Journal: Endocr Relat Cancer Date: 2017-07-21 Impact factor: 5.678
Authors: Luciana Ansaneli Naves; Lara Benigno Porto; João Willy Corrêa Rosa; Luiz Augusto Casulari; José Wilson Corrêa Rosa Journal: Pituitary Date: 2015-02 Impact factor: 4.107
Authors: Maria Rosaria Ambrosio; Irene Gagliardi; Sabrina Chiloiro; Ana Gonçalves Ferreira; Marta Bondanelli; Antonella Giampietro; Antonio Bianchi; Laura De Marinis; Maria Fleseriu; Maria Chiara Zatelli Journal: Endocrine Date: 2020-02-14 Impact factor: 3.633
Authors: Konstantina Vouzouneraki; Karl A Franklin; Maria Forsgren; Maria Wärn; Jenny Tiberg Persson; Helena Wik; Christina Dahlgren; Ann-Sofie Nilsson; Caroline Alkebro; Pia Burman; Eva-Marie Erfurth; Jeanette Wahlberg; Anna-Karin Åkerman; Charlotte Høybye; Oskar Ragnarsson; Britt Edén Engström; Per Dahlqvist Journal: Endocrine Date: 2018-07-31 Impact factor: 3.633